NasdaqGS:IONSBiotechs
Ionis (IONS) Begins First ION337 Trial In Dravet Syndrome Patients
Ionis Pharmaceuticals (NasdaqGS:IONS) has dosed the first participant in the Phase 1-2 ASCEND trial of ION337 for Dravet syndrome.
The study marks the first clinical evaluation of ION337, a next generation RNA targeted therapy candidate.
ION337 has FDA Fast Track designation for Dravet syndrome, a rare seizure disorder with no approved disease modifying treatments.
For investors following Ionis Pharmaceuticals, this new trial adds a fresh data point to the company’s rare disease portfolio...